Muskulamin (muscle bioregulator)

Muskulamin is a peptide preparation derived from young animal skeletal-muscle tissue, intended to support muscle recovery and function within the Khavinson cytomedin framework.

Muskulamin sits in the older "cytomedin" branch of the Khavinson bioregulator framework — peptide preparations extracted from young animal tissue rather than synthesized as defined short peptides. The cytomedin tradition predates the more recent short-peptide (cytogen) program and overlaps with it conceptually.

The cytomedin framework proposes that tissue-extract peptide preparations carry tissue-specific regulatory information that supports function in the same tissue type when administered. Independent Western validation of this concept is limited.^[1]

As a tissue-extract mixture, pharmacokinetics are complex and component-specific. Most clinical use is described in Russian-language pharmacology literature.

The peer-reviewed literature on Muskulamin is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).

This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.

Available as oral capsules / tablets in supplement form in jurisdictions where it's sold.

Muskulamin represents the older cytomedin branch of the Khavinson tradition — peptide preparations from animal tissue rather than synthetic short peptides. The framework is conceptually interesting and has a real clinical-experience base in its originating jurisdictions, but the Western evidence-grading bar has not been cleared for individual claims about this preparation.